KAPA Kairos Pharma, LTD.
Pharmaceutical Preparations · NYSE · SEC CIK 1962011 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-26.3%
TTM EPS YoY83.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-110.8%
ROA-102.8%
ROIC (approx.)-363.5%
Asset turnover—
Leverage & solvency
Liabilities / assets11.3%
Debt / equity0.00x
Current ratio6.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-36.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $2.13M | $414,000 |
| SG&A expense | $3.44M | $1.93M |
| Operating income | -$5.57M | -$2.34M |
| Interest expense | — | $35,000 |
| Net income | -$5.45M | -$2.60M |
| EPS (basic) | -0.30 | -0.23 |
| EPS (diluted) | -0.30 | -0.23 |
| Weighted avg. shares (diluted) | 18.43M | 11.36M |
| Balance sheet | ||
| Cash & equivalents | $4.49M | $1.27M |
| Current assets | $5.39M | $4.17M |
| Intangibles | $62,000 | $222,000 |
| Total assets | $6.54M | $5.77M |
| Current liabilities | $199,000 | $992,000 |
| Total liabilities | $199,000 | $992,000 |
| Shareholders' equity | $6.34M | $4.78M |
| Shares outstanding | 2.97M | 13.74M |
| Cash flow statement | ||
| Operating cash flow | -$3.44M | -$3.96M |
| Financing cash flow | $6.66M | $5.13M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.